Steady-state pharmacokinetics of zidovudine in Chinese HIV-infected patients  

作　　者：LIU Li-feng WANG Lu FU Qiang ZHU Zhu XIE Jing HAN Yang LIU Zheng-yin YE Min LI Tai-sheng 

机构地区：[1]Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China [2]Department of Pharmacology , Peking Union Medical College Hospital, Peking Union Medical College, Beijing 100730, China [3]Chinese Academy of Medical Sciences, STD/AIDS Research Center, Beijing You An Hospital, Capital Medical University, Beijing 100071, China

出　　处：《Chinese Medical Journal》2012年第11期1931-1935,共5页中华医学杂志（英文版）

基　　金：This study was supported by the grants from the National Key Technologies R＆D Program for the llth Five-year Plan （No. 2008ZX10001-006） and the National Natural Science Foundation of China （No. 81071372）.

摘　　要：Background The pharmacokinetics of zidovudine （AZT） are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed to characterize the steady-state pharmacokinetics of AZT in a Chinese set-up. Methods Eleven Chinese HIV-infected patients were involved in the steady-state pharmacokinetic study. In total, 300 mg of AZT, as a part of combination therapy, was given to patients, and serial blood samples were collected for 12 hours. The samples were measured by a high-performance liquid chromatography （HPLC） assay, and the results were analyzed by both the non-compartment model and the one-compartment model. Results The Cmax of AZT in Chinese patients was higher than that in non-Asian patients. The half-life of AZT, analyzed by the non-compartment model （P=-0.02）, in male patients （（1.02±0.22） hours） was shorter than that of AZT in female patients （（1.55±0.29） hours）. The AZT clearance, analyzed by the one-compartment model （P=0.045）, in male patients （（262.60±28.13） L/h） was higher than that in female patients （（195.85±60.51） L/h）. Conclusion The present study provides valuable information for the clinical practice of AZT-based highly active antiretroviral therapy in a Chinese set-up.Background The pharmacokinetics of zidovudine （AZT） are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed to characterize the steady-state pharmacokinetics of AZT in a Chinese set-up. Methods Eleven Chinese HIV-infected patients were involved in the steady-state pharmacokinetic study. In total, 300 mg of AZT, as a part of combination therapy, was given to patients, and serial blood samples were collected for 12 hours. The samples were measured by a high-performance liquid chromatography （HPLC） assay, and the results were analyzed by both the non-compartment model and the one-compartment model. Results The Cmax of AZT in Chinese patients was higher than that in non-Asian patients. The half-life of AZT, analyzed by the non-compartment model （P=-0.02）, in male patients （（1.02±0.22） hours） was shorter than that of AZT in female patients （（1.55±0.29） hours）. The AZT clearance, analyzed by the one-compartment model （P=0.045）, in male patients （（262.60±28.13） L/h） was higher than that in female patients （（195.85±60.51） L/h）. Conclusion The present study provides valuable information for the clinical practice of AZT-based highly active antiretroviral therapy in a Chinese set-up.

关 键 词：human immunodeficiency virus  steady-state PHARMACOKINETICS ZIDOVUDINE Chinesepatients 

分 类 号：R512.91[医药卫生—内科学]